



Contrast Enhanced Mammography In The Diagnosis Of Breast Cancer

Essay

*Submitted for partial fulfillment of master degree of
radiodiagnosis*

Presented by

Sara Mohammed Elmeseiry
M.B., B.Ch

Supervised by

Prof. Dr. Sherine Kadry Amin

Professor of Radiodiagnosis

Faculty of Medicine, Ain Shams University

Dr. Walid Mohamed Abd Elhameed Hetta

Assistant Professor Of Radiodiagnosis

Faculty of Medicine, Ain Shams University

**Faculty of Medicine
Ain Shams University**

2017



دور أشعه الثدي الماموجرام باستخدام الصبغة في تشخيص سرطان الثدي

رسالة

توطئة للحصول علي درجة الماجستير في الاشعه

التشخيصيه

مقدمة من

الطبيبة/ ساره محمد المسيري

بكالوريوس الطب و الجراحة

تحت إشراف

أ.د/ شيرين قدرى امين

استاذ الاشعه التشخيصيه

كلية الطب- جامعة عين شمس

د/ وليد محمد عبد الحميد حته

أستاذ مساعد الاشعه التشخيصيه

كلية الطب- جامعة عين شمس

كلية الطب

جامعة عين شمس

٢٠١٧

بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ

قالوا

سبحانك لا علم لنا
إلا ما علمتنا إنك أنت
العليم العظيم

صدق الله العظيم

سورة البقرة الآية: ٣٢



Acknowledgement

*First and foremost thanks to **ALLAH**, the Most Merciful.*

*I would like to express my deepest appreciation and respect to **Prof. Dr. Sherine Kadry Amin**, Professor of Radiodiagnosis, Faculty of Medicine, Ain Shams University for her priceless effort, generous guidance and patience.*

*I am grateful to **Dr. Walid Hetta**, Assistant Professor of Radiodiagnosis, Faculty of Medicine, Ain Shams University for her help, supervision and great effort.*

Finally, I would like to thank my precious family, friends and colleagues for believing in me and their continuous support.

Contents

Subjects	Page
• List of Abbreviations	I
• List of table	II
• List of Figures	III
• Introduction	1
• Aim of the Work.....	5
• Review of literature:	
Chapter 1: Anatomy of breast	6
Chapter 2: Pathology of suspicious breast masses.....	23
Chapter 3: Technique of contrast enhanced mammography	39
Chapter 4: Manifestations of suspicious breast masses by contrast enhanced mammography with illustrative cases	52
• Summary	84
• Conclusion	86
• References	87
• Arabic Summary	-

List of Abbreviations

ACC	: Adenoid cystic carcinoma
ACR	: American College of Radiology
ACS	: American cancer society
AGD	: Avarage glandular dose
AGD	: Average glandular dose
BI-RADS	: Breast Imaging-Reporting and Data System
BMI	: Body mass index
CC	: Cranio-caudal
CEDM	: Contrast Enhanced Digital Mammography
CESM	: Contrast enhanced spectral mammography
DCIS	: Ductal carcinoma in situ
DE-CEM	: Dual energy Contrast Enhanced Mammography
ER	: Estrogen receptor
Gd	: Gadolinium
HRT	: Hormonal releasement therapy
IDC	: Invasive duct carcinoma
ILC	: Invasive lobular carcinoma
LCIS	: Lobular carcinoma in situ
LN	: Lymph node
MG	: Mammography
MLO	: Medio-lateral oblique
MPS	: Malignancy potential score
MRI	: Magnetic resonance imaging
NCI	: Nathional cancer institute
TNM	: Tumor,Node,Metastasis
UOQ	: Upper outer Quadrant
US	: Ultra sonography

List of Table

<i>Tab. No.</i>	<i>Subject</i>	<i>Page</i>
Table (1)	TNM staging of breast cancer	38
Table (2)	BI-ARDS SCORE	55
Table (3)	Advantage of contrast enhanced mammography versus MRI	68

List of Figures

Fig. No.	Subject	Page
Fig. (1)	The Position of mammary line	6
Fig. (2)	Over view of the breast	8
Fig. (3)	The glandular breast parenchyma	10
Fig. (4)	Intra and Extralobular ducts	12
Fig. (5)	Artarial supply of the breast	14
Fig. (6)	Blood Supply of the breast	15
Fig. (7)	Draining LNs of the breast	16
Fig. (8)	Entirly fatty breast ACR(A)	20
Fig. (9)	Scattered fibroglandular densities ACR(B)	20
Fig. (10)	Heterogenously dense breast ACR(C)	21
Fig. (11)	Extremely dense breast ACR (D)	22
Fig. (12)	Topographic considerations in breast cancer	23
Fig. (13)	Imaging procedure of dual energy CEDM	46
Fig. (14)	Temporal subtraction contrast enhanced mammography	48
Fig. (15)	Conventional and contrast enhanced mammography in pleomorphic calcificationof invasive ductal carcinoma	59
Fig. (16)	Conventional and contrast enhanced mammography of normal glandular tissue mimicking cancer	60
Fig. (17)	Conventional and contrast enhanced mammography of invasive ductal carcinoma, non-obvious in the conventional study	62
Fig. (18)	Conventional and contrast enhanced mammography of multiple invasive ductal carcinoma	63
Fig. (19)	Conventional and contrast enhanced mammography of papilloma and infiltrating ductal carcinoma	64
Fig. (20)	contrast enhanced mammography before and after chemotherapyshow complete remission	65

List of Figures

Fig. No.	Subject	Page
Fig. (21)	Artefacts in contrast enhanced mammography	71
Fig. (22)	Conventional and contrast enhanced mammography show mixed invasive lobular and invasive ductal carcinoma.	73
Fig. (23)	Conventional and contrast enhanced mammography representing multifocal invasive ductal carcinoma.	75
Fig. (24)	Conventional, contrast enhanced mammography after course of neo adjuvant chemo therapy show residual invasive lobular carcinoma .	76
Fig. (25)	Conventional and contrast enhanced mammography of invasive ductal carcinoma	77
Fig. (26)	Conventional, contrast enhanced mammography of granulomatous mastitis	78
Fig. (27)	Conventional and contrast enhanced mammography representing actual size of active lesion.	79
Fig. (28)	Conventional and contrast enhanced mammography showing no enhancement and absence of malignancy.	80
Fig. (29)	Conventional and contrast enhanced mammography showing benign post oprative changes (BI-RADS 2)	81
Fig. (30)	Conventional and contrast enhanced mammography showing false positive CEDM.	82
Fig. (31)	Conventional and contrast enhanced mammography showing false negative CEDM.	83

Introduction

Breast cancer is the most frequently diagnosed cause of death from cancer in women worldwide, the second leading cause of death from cancer in women in developed countries and the leading cause of death from cancer in low- and middle-income countries, where a high proportion of women present with advanced disease, which leads to a poor prognosis (*Ferlay et al., 2014*).

Established risk factors for breast cancer include age, family or personal history of breast cancer or of precancerous lesions, reproductive factors, hormonal treatment, alcohol consumption, obesity (for postmenopausal breast cancer only), exposure to ionizing radiation, and genetic predisposition (*Colditz and Bohlke 2014*).

Screening for breast cancer aims to reduce mortality from this cancer, as well as the morbidity associated with advanced stages of the disease, through early detection in asymptomatic women. The key to achieving the greatest potential effects from this screening is providing early access to effective diagnostic and treatment services. Comprehensive quality assurance is essential to maintaining an appropriate balance between benefits and harms (*Sankaranarayanan and Swaminathan 2010*).

Number of screening tests have been employed, including clinical and self breast exams, mammography,

genetic screening, ultrasound, and magnetic resonance imaging (*Kösters and Göttsche, 2003*).

Mammography is a common screening method, since it is relatively fast and widely available in developed countries. Mammography is a type of radiography used on the breasts. It is typically used for two purposes: to aid in the diagnosis of a woman who is experiencing symptoms or has been called back for follow-up views (called diagnostic mammography), and for medical screening of apparently healthy women (called screening mammography).

Mammography has some limitations, such as lesions masked by normal fibroglandular tissue, lesions seen on only one view, and subtle architectural distortions. Partly because of these limitations, mammography misses about 20% of invasive breast cancers (*Dromain et al., 2012*).

Initial mammographic images themselves are not usually enough to determine the existence of adisease with certainty. If a finding or spot seems suspicious, your radiologist may recommend further diagnostic studies.

Contrast agent has been used for many years in both computed tomography and magnetic resonance imaging examinations to explore angiogenesis in breast carcinoma by tracking the uptake and washout of contrast agent in tissues (*Dromain et al., 2012*).

However, conventional CT results in a high-radiation dose to the breast and chest wall. Breast MRI using gadolinium-based contrast agents is currently considered the most sensitive imaging technique for the detection of breast carcinoma. However, breast MRI has a variable specificity and positive predictive value and is more time-consuming and more expensive than mammography (*Dromain et al., 2012*).

Contrast-enhanced mammography is a new breast imaging technique that has been developed to visualize iodinated contrast agent uptake in the breast. It uses contrast agent to make cancers that are not visible on standard mammograms show up as enhancing areas (*Jochelson et al., 2013*).

It works as breast MRI, which also done with contrast, the cancer takes up more of contrast agent than surrounding tissue causing the cancer to show up as a white area on the mammogram (*Jochelson et al., 2013*).

Several clinical studies have shown a significantly higher sensitivity for the detection of invasive breast cancers for contrast-enhanced mammography than mammography, the ability of CEM to accurately assess the size of the lesion compared to histology and high sensitivity of CEM for the detection of multifocal disease (*Dromain et al., 2011*).

Compared to MRI, CEM has similar sensitivity but better specificity for detection of breast cancer (*Fallenberg et al., 2014*).

CEM less expensive equipment so it can be performed at less cost. It is also shorter examination, lasting about 5 minutes, versus 30-40 minutes for an MRI (*Mcdonald et al., 2015*).

Aim of the work

To discuss contrast enhanced mammography as new technique that would improve clinical performance of mammography and to highlight its sensitivity and accuracy in the diagnosis of breast cancer.

.

Anatomy of the breast

Development of the breast

The epithelial mammary bud appearing at a gestational age of 35 days. by day 37 this become a mammary line extending from the axilla through to the inguinal region (**Fig 1**). (*Sadler, 2004*).

Usually invagination of the thoracic mammary bud into the mesenchyme occurs by day 49, with involution of the remaining mammary line. Nipple formation begins at 56 day and primitive ducts (mammary sprouts) develop at 84 days with canalization occurring at about the 150th day (*Williams, 1995*).




Fig. (1): The position of the mammary line (*Sadler, 2004*)

Persistence of remnants of the mammary line may give rise to accessory nipples (polythelia). They are found along of the mammary line and are commonly mistaken for